Record Information |
---|
Version | 5.0 |
---|
Status | Detected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:49 UTC |
---|
Update Date | 2022-03-07 02:51:37 UTC |
---|
HMDB ID | HMDB0014426 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Lidocaine |
---|
Description | Lidocaine is only found in individuals that have used or taken this drug. It is a local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of procaine but its duration of action is shorter than that of bupivacaine or prilocaine. [PubChem]Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action. Lidocaine alters signal conduction in neurons by blocking the fast voltage gated sodium (Na+) channels in the neuronal cell membrane that are responsible for signal propagation. With sufficient blockage the membrane of the postsynaptic neuron will not depolarize and will thus fail to transmit an action potential. This creates the anaesthetic effect by not merely preventing pain signals from propagating to the brain but by aborting their birth in the first place. |
---|
Structure | CCN(CC)CC(=O)NC1=C(C)C=CC=C1C InChI=1S/C14H22N2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17) |
---|
Synonyms | Value | Source |
---|
2-(Diethylamino)-2',6'-acetoxylidide | ChEBI | 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide | ChEBI | alpha-Diethylamino-2,6-dimethylacetanilide | ChEBI | Lidoderm | ChEBI | Dentipatch | Kegg | Xylocaine | Kegg | a-Diethylamino-2,6-dimethylacetanilide | Generator | Α-diethylamino-2,6-dimethylacetanilide | Generator | Dilocaine | HMDB | L-Caine | HMDB | 2-2ETN-2MePhAcN | HMDB | Astrazeneca brand OF lidocaine | HMDB | Dalcaine | HMDB | Jenapharm brand OF lidocanine hydrochloride | HMDB | Lidocaine carbonate | HMDB | Lidocaine hydrochloride | HMDB | Lidocaine monohydrochloride | HMDB | Lidocaine sulfate (1:1) | HMDB | Lignocaine | HMDB | Novocol brand OF lidocaine hydrochloride | HMDB | Octocaine | HMDB | Xylocitin | HMDB | Lidocaine carbonate (2:1) | HMDB | Strathmann brand OF lidocaine hydrochloride | HMDB | Xyloneural | HMDB | Lidocaine hydrocarbonate | HMDB | Lidocaine monoacetate | HMDB | Lidocaine monohydrochloride, monohydrate | HMDB | Xylesthesin | HMDB |
|
---|
Chemical Formula | C14H22N2O |
---|
Average Molecular Weight | 234.3373 |
---|
Monoisotopic Molecular Weight | 234.173213336 |
---|
IUPAC Name | 2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide |
---|
Traditional Name | lidocaine |
---|
CAS Registry Number | 137-58-6 |
---|
SMILES | CCN(CC)CC(=O)NC1=C(C)C=CC=C1C |
---|
InChI Identifier | InChI=1S/C14H22N2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17) |
---|
InChI Key | NNJVILVZKWQKPM-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as m-xylenes. These are aromatic compounds that contain a m-xylene moiety, which is a monocyclic benzene carrying exactly two methyl groups at the 1- and 3-positions. |
---|
Kingdom | Organic compounds |
---|
Super Class | Benzenoids |
---|
Class | Benzene and substituted derivatives |
---|
Sub Class | Xylenes |
---|
Direct Parent | m-Xylenes |
---|
Alternative Parents | |
---|
Substituents | - M-xylene
- Tertiary aliphatic amine
- Tertiary amine
- Organic 1,3-dipolar compound
- Propargyl-type 1,3-dipolar organic compound
- Carboximidic acid derivative
- Carboximidic acid
- Organic nitrogen compound
- Organic oxygen compound
- Organopnictogen compound
- Hydrocarbon derivative
- Organooxygen compound
- Organonitrogen compound
- Amine
- Aromatic homomonocyclic compound
|
---|
Molecular Framework | Aromatic homomonocyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 68.5 °C | Not Available | Boiling Point | 181 °C | Not Available | Water Solubility | 0.59 g/L | Not Available | LogP | 2.1 | Not Available |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross SectionsAdduct Type | Data Source | CCS Value (Å2) | Reference |
---|
[M+H]+ | CBM | 157.7 | 30932474 |
|
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Lidocaine,1TMS,isomer #1 | CCN(CC)CC(=O)N(C1=C(C)C=CC=C1C)[Si](C)(C)C | 1721.5 | Semi standard non polar | 33892256 | Lidocaine,1TMS,isomer #1 | CCN(CC)CC(=O)N(C1=C(C)C=CC=C1C)[Si](C)(C)C | 1852.1 | Standard non polar | 33892256 | Lidocaine,1TMS,isomer #1 | CCN(CC)CC(=O)N(C1=C(C)C=CC=C1C)[Si](C)(C)C | 2218.2 | Standard polar | 33892256 | Lidocaine,1TBDMS,isomer #1 | CCN(CC)CC(=O)N(C1=C(C)C=CC=C1C)[Si](C)(C)C(C)(C)C | 1991.0 | Semi standard non polar | 33892256 | Lidocaine,1TBDMS,isomer #1 | CCN(CC)CC(=O)N(C1=C(C)C=CC=C1C)[Si](C)(C)C(C)(C)C | 2061.3 | Standard non polar | 33892256 | Lidocaine,1TBDMS,isomer #1 | CCN(CC)CC(=O)N(C1=C(C)C=CC=C1C)[Si](C)(C)C(C)(C)C | 2348.3 | Standard polar | 33892256 |
|
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Lidocaine GC-MS (Non-derivatized) - 70eV, Positive | splash10-00xr-7900000000-a9354c2fae02587e1a3f | 2017-08-28 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Lidocaine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | MS | Mass Spectrum (Electron Ionization) | splash10-000i-9000000000-38a47958df650b972703 | 2014-09-20 | Not Available | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Lidocaine 10V, Negative-QTOF | splash10-001i-0390000000-5a1868d5a3e74f540745 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lidocaine 20V, Negative-QTOF | splash10-01x0-0970000000-a6a212497ff43f58ed7c | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lidocaine 40V, Negative-QTOF | splash10-000b-1900000000-673b704f5bbb89458521 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lidocaine 30V, Negative-QTOF | splash10-0002-1930000000-f3734f8ffe8cb1de0df6 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lidocaine LC-ESI-QTOF , positive-QTOF | splash10-000i-0090000000-7a90fe8d9b35b745cfce | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lidocaine LC-ESI-QTOF , positive-QTOF | splash10-001i-0920000000-f9f648594c0f1642cc4c | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lidocaine LC-ESI-QTOF , positive-QTOF | splash10-0089-0900000000-5716ccc63e48696473bc | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lidocaine LC-ESI-ITFT , positive-QTOF | splash10-000i-9000000000-9d18ae1cd0a81ee63d35 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lidocaine LC-ESI-ITFT , positive-QTOF | splash10-000i-0090000000-83bc5908a67b3ba4b826 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lidocaine LC-ESI-ITFT , positive-QTOF | splash10-000i-8090000000-e305bfb01d615662d8a1 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lidocaine LC-ESI-ITFT , positive-QTOF | splash10-000i-9000000000-eab27554002663b2d3fd | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lidocaine LC-ESI-ITFT , positive-QTOF | splash10-000i-9000000000-1b684e31ff74300b808f | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lidocaine LC-ESI-ITFT , positive-QTOF | splash10-000i-9000000000-b39af34b526d79a4b07b | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lidocaine LC-ESI-ITFT , positive-QTOF | splash10-000i-9000000000-9466a1403df493f5b6e9 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lidocaine LC-ESI-ITFT , positive-QTOF | splash10-000i-0090000000-c773b8e10c70518882c1 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lidocaine LC-ESI-ITFT , positive-QTOF | splash10-000i-8090000000-00b6d0139ebe20cdb189 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lidocaine LC-ESI-ITFT , positive-QTOF | splash10-000i-9000000000-0b33ce49934844438e43 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lidocaine LC-ESI-ITFT , positive-QTOF | splash10-000i-9000000000-502494c9626d1dca25d1 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lidocaine LC-ESI-ITFT , positive-QTOF | splash10-000i-9000000000-b39af34b526d79a4b07b | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lidocaine LC-ESI-ITFT , positive-QTOF | splash10-000i-9000000000-86c007695ec40849f993 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lidocaine LC-ESI-ITFT , positive-QTOF | splash10-000i-9000000000-7f630b7fa4e36c59e0d2 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lidocaine LC-ESI-QTOF , positive-QTOF | splash10-000i-9060000000-b5aef137d8e488097fc4 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lidocaine LC-ESI-QTOF , positive-QTOF | splash10-000i-9000000000-b21ee69ce889ba36b5e5 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lidocaine LC-ESI-QTOF , positive-QTOF | splash10-000i-9000000000-9d7555c18e41a90508a5 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lidocaine LC-ESI-QQ , positive-QTOF | splash10-000i-0090000000-3dd6e01da50ad1a66b2f | 2017-09-14 | HMDB team, MONA | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
|
---|
Biological Properties |
---|
Cellular Locations | |
---|
Biospecimen Locations | |
---|
Tissue Locations | |
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB00281 | | details | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Urine | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB00281 | | details |
|
---|
Abnormal Concentrations |
---|
| |
Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Colorectal cancer | | details | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Colorectal cancer | | details |
|
---|
Predicted Concentrations |
---|
| |
Blood | 0.000 uM | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities | Blood | 0.000 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities |
|
---|
Associated Disorders and Diseases |
---|
Disease References | Colorectal cancer |
---|
- Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016. [PubMed:27015276 ]
- Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18. [PubMed:25037050 ]
|
|
---|
Associated OMIM IDs | |
---|
External Links |
---|
DrugBank ID | DB00281 |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | Not Available |
---|
KNApSAcK ID | Not Available |
---|
Chemspider ID | 3548 |
---|
KEGG Compound ID | C07073 |
---|
BioCyc ID | Not Available |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Lidocaine |
---|
METLIN ID | Not Available |
---|
PubChem Compound | 3676 |
---|
PDB ID | LQZ |
---|
ChEBI ID | 6456 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | Not Available |
---|
MarkerDB ID | Not Available |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Not Available |
---|
Material Safety Data Sheet (MSDS) | Download (PDF) |
---|
General References | - Thomson PD, Melmon KL, Richardson JA, Cohn K, Steinbrunn W, Cudihee R, Rowland M: Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. Ann Intern Med. 1973 Apr;78(4):499-508. [PubMed:4694036 ]
- Khaliq W, Alam S, Puri N: Topical lidocaine for the treatment of postherpetic neuralgia. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD004846. [PubMed:17443559 ]
- Elshenawy S, Pinney SE, Stuart T, Doulias PT, Zura G, Parry S, Elovitz MA, Bennett MJ, Bansal A, Strauss JF 3rd, Ischiropoulos H, Simmons RA: The Metabolomic Signature of the Placenta in Spontaneous Preterm Birth. Int J Mol Sci. 2020 Feb 4;21(3). pii: ijms21031043. doi: 10.3390/ijms21031043. [PubMed:32033212 ]
|
---|